GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amarin Corp PLC (NAS:AMRN) » Definitions » 5-Year Yield-on-Cost %

Amarin (Amarin) 5-Year Yield-on-Cost % : 0.00 (As of Apr. 28, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Amarin 5-Year Yield-on-Cost %?

Amarin's yield on cost for the quarter that ended in Dec. 2023 was 0.00.


The historical rank and industry rank for Amarin's 5-Year Yield-on-Cost % or its related term are showing as below:



AMRN's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.22
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Amarin's 5-Year Yield-on-Cost %

For the Drug Manufacturers - General subindustry, Amarin's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amarin's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amarin's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Amarin's 5-Year Yield-on-Cost % falls into.



Amarin 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Amarin is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Amarin  (NAS:AMRN) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Amarin 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Amarin's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Amarin (Amarin) Business Description

Traded in Other Exchanges
Address
112-114 St Stephens Green, Iconic Offices, The Greenway, Block C Ardilaun Court, Dublin, IRL, D02 TD28
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its lead product includes Vascepa.
Executives
Steven B Ketchum officer: Chief Scientific Officer 2483 EAST BAYSHORE ROAD, SUITE 100, PALO ALTO CA 94303
Patrick Holt director, officer: See Remarks C/O AMARIN CORPORATION, SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2 L2 D02 VK60
Oliver O'connor director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Paul Cohen director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Diane E. Sullivan director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Louis Iii Sterling director C/O AMARIN CORPORATION PLC, 77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2 L2 D02 VK60
Keith Horn director 204 STATE ROUTE 17B, P.O. BOX 5013, C/O MONTICELLO CASINO AND RACEWAY, MONTICELLO NY 12701
Patrice Eadon Bonfiglio director 488 HAVILAND ROAD, STAMFORD CT 06903
Mark Dipaolo director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Thomas Charles Reilly officer: SVP and CFO C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Aaron Berg officer: EVP, President US C/O AMARIN PHARMA, INC., 1430 ROUTE 206, BEDMINSTER NJ 07921
Karim Mikhail director, officer: President and CEO C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER NJ 08807
Olsen Per Wold director C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Murray Stewart director C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3